We love to hear from our listeners. Send us a message.
BlueRock Therapeutics' President and CEO Seth Ettenberg, Ph.D. talks to Cell & Gene: The Podcast listeners about the company's Phase 1 Clinical Trial for Advanced Parkinson’s Disease. Ettenberg also covers the most promising therapeutic applications for iPSCs currently in development as well as the major regulatory challenges that the field faces for their clinical use. We also cover how far iPSCs have come and what future progress may entail.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn
Cell & Gene: The Podcast